Our findings add to the body of evidence that SGLTs, and in particular SGLT2, may be involved in the pathogenesis of epilepsy and that SGLT2 inhibitors such as dapagliflozin can be utilized as antiepileptic drugs. Here, SLC5A2 is linked to epilepsy.